The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Sionna Therapeutics近日宣布了其在美国纳斯达克上市的计划，股票代码定为“SION”。这家专注于囊性纤维化（CF）治疗的公司，希望通过此次上市进一步推动其研发进程。 Sionna ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

雷递网 雷建平 1月29日Sionna Therapeutics日前递交招股书，准备在美国纳斯达克上市，股票代码为：“SION” 。9个月净亏4584万美元Sionna Therapeutics成立于2019年，是一家临床阶段生命科学公司，致力于通过使 CFTR（与CF疾病进展相关的关键蛋白）的功能正常化来开发高效和差异化的囊性纤维化 (CF) 治疗方法。Sionna ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Sionna Therapeutics (SION), which is developing drugs to treat cystic fibrosis, has filed to raise $100M through an initial public offering. While Sionna (SION) didn't disclose terms in its SEC filing ...

智通财经APP获悉，开发囊性纤维化新疗法的第二阶段生物技术公司Sionna Therapeutics上周五向美国证券交易委员会提交了首次公开募股申请，预计将筹集高达1亿美元的资金。 Sionna正在开发使囊性纤维化跨膜传导调节蛋白 (CFTR)功能正常化的治疗方法，作为CF患者的治疗方法。该公司的目标是通过直接稳定CFTR的核苷酸结合结构域1 ...

Sionna Therapeutics日前递交招股书，准备在美国纳斯达克上市，股票代码为：“SION” 。 Sionna Therapeutics成立于2019年，是一家临床阶段生命科学公司 ...

Sionna Therapeutics is working on therapies for cystic fibrosis, several of which are in early-stage testing. Odyssey Therapeutics aims to tap Wall Street to develop targeted drugs for immune ...